BONT/A promotes recovery from paraplegia
The invention demonstrates that Botulinum neurotoxin type A (BoNT/A) is an efficacious therapeutic treatment after spinal trauma. A single spinal administration of BoNT/A after the traumatic event decreases inflammation, confers neuroprotection, preserves neurons from cell death and promotes regeneration leading to a complete recovery from paralysis (paraplegia/tetraplegia) and restoration of sensitivity.
The CNR team coordinated by dott. Sara Marinelli (CNR – Cell Biology and Neurobiology Institute) is focusing its research on pain transmission and inflammatory and chronic pain modulation, achieving important and innovative results in using of toxins of bacterial origin as new drug with new therapeutic use. In particular have been demonstrated that Botulinum neurotoxin type A (BoNT/A), a potent biological toxin widely used in clinical practice for treatment of various disorders, is able to contrast neuropathic pain (Nep) caused by peripheral nerve injury. The CNR team demonstrates that, in a mouse model, BoNT/A is an efficacious treatment for a complete recovery from paralysis (paraplegia/tetraplegia) and restoration of sensitivity, a novelty in the treatment for spinal injuries and symptoms associated with them, from pain to paralysis.
- Treatment for spinal injuries and symptoms associated with them, from pain to paralysis;
- Recovery from paralysis (paraplegia/tetraplegia) and restoration of sensitivity.
- A new therapeutic use of a molecule (BoNT/A) already widely used in clinical practice, which greatly reduces the time for translation to patients Furthermore, there are already several commercial formulations for the administration of BoNT/A;
- No side effects at therapeutic doses
- It is certainly analgesic/anti-inflammatory and it prevents neuropathic pain, all of which are symptoms associated with SCI.